Featured Research

from universities, journals, and other organizations

Researchers Demonstrate That Cox-2 Inhibits Angiogenisis In Tumor Cells

Date:
May 29, 1998
Source:
Vanderbilt University Medical Center
Summary:
Aspirin's preventive effects on colon cancer may result from its influence on the development of blood vessels needed for tumor growth.

Aspirin's preventive effects on colon cancer may result from its influence on the development of blood vessels needed for tumor growth, a Vanderbilt Cancer Center researcher reports in the Friday, May 29, issue of the journal Cell. The work was done jointly by Dr. Raymond N. DuBois, Mina Cobb Wallace Professor of Gastroenterology and Cancer Prevention and director of the division of Gastroenterology, and colleagues at the Osaka University School of Medicine in Japan. The researchers demonstrated two ways in which aspirin can inhibit angiogenesis, an important component in the development and spread of cancer. "What we found is that NSAIDs can work in two ways -- by inhibiting the enzyme cyclooxygenase-2 (COX-2) in the tumor cells, which then prevents production of factors that prompt angiogenesis, and by inhibiting cyclooxygenase-1 (COX-1) in endothelial cells, which form the blood vessels that grow into the tumor," DuBois said. The research builds on earlier work by DuBois and his colleagues that suggested aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) help prevent colon cancer by inhibiting COX-2, which they found to be elevated in colon cancer cells. However, this new research suggests that COX-1 -- and the ability of aspirin and NSAIDs to target it as well -- may also be involved. These studies were carried out in an in vitro model of angiogenesis involving a chamber with colon cancer cells on the bottom and endothelial cells on the top, separated by a porous collagen membrane. In a series of experiments, the researchers first compared colon cancer cells that overexpress COX-2 to control cells. They found that the COX-2-positive colon carcinoma cells produced angiogenic factors that, in turn, stimulated migration of the endothelial cells across the collagen gel. These COX-2-positive colon cancer cells also prompted the endothelial cells to begin to form tube-like structures, the first steps of blood vessel development. Control cells had little effect. The researchers then studied whether these effects would be inhibited by antibodies to specific angiogenic factors, a selective COX-2 inhibitor called NS-396 or aspirin. They found antibodies which neutralized some of the angiogenic factors inhibited angiogenesis in vitro. Then, to examine the specificity of the effects of the COX-2 inhibitor, the researchers evaluated colon cancer cells that express neither COX-1 nor -2. These cells also produced angiogenic factors that prompted endothelial cell migration and tube formation. Again, only combination of at least two antibodies to specific angiogenic factors inhibited tube formation, while antibodies to individual factors had no effect. Treatment with aspirin and the COX-2 inhibitor did not affect the levels of these angiogenic factors, and the COX-2 inhibitor had no inhibiting effect on tube formation. Suprisingly, however, aspirin did inhibit the angiogenic effects. "It was really an unexpected finding," DuBois said. "There's long been a question about how aspirin reduces the risk for developing colon cancer, and in this model system, we found two ways in which that might be happening. If we can better understand the mechanism involved, we may be able to find other ways to effectively block angiogenesis. However, we need to keep in mind that these results will have to be validated in an in vivo tumor model to fully understand the significance of these findings." Chris Williams, a student in DuBois' lab who is pursuing his M.D./Ph.D., is following up the research with studies in animal tumor models.


Story Source:

The above story is based on materials provided by Vanderbilt University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Vanderbilt University Medical Center. "Researchers Demonstrate That Cox-2 Inhibits Angiogenisis In Tumor Cells." ScienceDaily. ScienceDaily, 29 May 1998. <www.sciencedaily.com/releases/1998/05/980526175839.htm>.
Vanderbilt University Medical Center. (1998, May 29). Researchers Demonstrate That Cox-2 Inhibits Angiogenisis In Tumor Cells. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/1998/05/980526175839.htm
Vanderbilt University Medical Center. "Researchers Demonstrate That Cox-2 Inhibits Angiogenisis In Tumor Cells." ScienceDaily. www.sciencedaily.com/releases/1998/05/980526175839.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins